VYST — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-13

• RxAir promotes a healthy lifestyle through the use of its innovative, patented ViraTech air purification technology, thereby improving the quality of life of each and every customer. Independently tested by the U.S. Environmental Protection Agency (“EPA”) and U.S. Food and Drug Administration (“FDA”…

• The Company’s RxAir product line use 48 inches of high-intensity germicidal UV lamps that destroy bacteria, viruses and other germs instead of just trapping them, setting it apart from ordinary air filtration units. RxAir is one of the few UV air purifiers that have been proven in independent EPA- a…

• Comparison of the Three Months Ended March 31, 2026 with the Three Months Ended March 31, 2025

• Revenues for the three months ended March 31, 2026 and 2025 were $6,147 and $12,657, respectively, for a decrease of $6,510 or 51.4%. The decrease in revenues was due in part to reduced channel sales. The Company will be reviewing its pricing and sales strategies in the second and third quarter of 2…

• The Company reported gross profit of $4,272 for the three-month period ended March 31, 2026 compared to gross profit of $4,307 for the three-month period ended March 31, 2025, a decrease of $35 or 0.8%.

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• The three main businesses of Vystar are RxAir, a line of FDA cleared class II medical air purifiers; Vytex, patented allergy free natural rubber latex, which includes a line of mattress, toppers and pillows; and Fluid Energy Conversion (FEC), a patented technology that can be used in the medical, en…

• RxAir promotes a healthy lifestyle through the use of its innovative, patented and trademark ViraTech air purification technology, thereby improving the quality of life of each and every customer. Independently tested by the U.S. Environmental Protection Agency (“EPA”) and U.S. Food and Drug Adminis…

• The Company’s RxAir product line uses 48 inches of high-intensity germicidal UV lamps that destroy bacteria, viruses and other germs instead of just trapping them, setting it apart from ordinary air filtration units. RxAir is one of the few UV air purifiers that have been proven in independent EPA- …

• To ensure continued growth of its product lines, Vystar is exploring a reverse merger or other transaction of the RxAir division which would include a perpetual license from FEC, and a second spinout, sale or other transaction involving the Vytex and FEC divisions.

• Vystar’s board is currently in discussions to acquire a minority interest (less than 10%) in GOPAID.COM, LLC. (GOPAID). The primary goal of GOPAID is to tokenize real-world collectibles that can be traded on a blockchain, and work with music artists to help monetize their collections of memorabilia …

Text added vs the prior filing · source: 10-Q · 2026-05-13

• a) The Company does not have sufficient segregation of duties within the accounting department due to the small size of the Company.

• Lack of a functioning audit committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

• f) Lack of controls over identification, valuation and bifurcation of embedded features in debt instruments.

• Management expects to strengthen internal control during 2026 by developing stronger business and financial processes for accounting for transactions, which will enhance internal control for the Company.

Text removed vs the prior filing · source: 10-Q · 2025-11-12

• a) We have a lack of segregation of duties due to the small size of the Company.

• e) Lack of a functioning audit committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures. Management believes the lack of a functioning audit committee results in ineffective oversight in the establishment and monitoring of require…

• Management expects to strengthen internal control during 2025 by developing stronger business and financial processes for accounting for transactions, which will enhance internal control for the Company.